MESSAGE
Our laboratory is interested in discovering new therapeutic methods against advanced cancer based on host anti-cancer immunity.
Our interests focus in two main topics which include oncolytic virus and anti-cancer cell therapy.
We are using natural mutated herpes simplex virus, HF10 which has been studied in USA as well as in Japan. This oncolytic virus is well known for its effect on "continuous replication with infection of neighboring cells and killing cancer cells without any damage to normal cells". HF10 is drastically different from former virus vectors. Recent studies have shown that oncolytic virus affects host immune response against specific cancer antigens, therefore it inhibits systemic metastasis.
As for cell therapy, we are interested in genetically modified receptor T-cell lymphocytes, which target cancer specific antigens on cancer cell surface. Our laboratory is studying a new generation technology for genetically modified receptor T-cell lymphocyte using iPS. We are amassing basic research data and eager to make a bridge to clinical trials with the goal of making a substantial difference in each patient's prognosis.
NEWS & TOPICS
Sep. 2024
Dr.Naoe gave a presentation at the 83th Annual Meeting of the Japanese Cancer-Association(2024/9/19-21 Fukuoka).
July 2024
Patricia got the Award of ANGES for The young researcher at the 30th Annual Meeting of Japan Society of Gene and Cell Therapy (2024/7/16-18 Yokohama).
July 2024
Dr.Kasuya and Dr.Naoe gave a presentation at the 30th Annual Meeting of Japan Society of Gene and Cell Therapy (2024/7/16-18 Yokohama).
Feb. 2024
Our paper has been published in Molecular Oncology.
Nov. 2023
Mohamed, Mona, and Patricia1 gave a presentation at the 1st Annual Meeting of the Japan Society of Oncolytic Virus Therapy (2023/11/3 Tokyo Univ.).
Sep. 2023
Our review paper has been published inInternational Journal of Molecular Sciences.
Sep. 2023
Mohamed got the Award of ANGES for The young researcher at the 29th Annual Meeting of Japan Society of Gene and Cell Therapy (2023/9/11-13 Osaka).
Sep. 2023
Dr.Kasuya, Dr.Naoe, Dr. Matsumura, Mohamed, Mona, and Patricia gave a presentation at the 29th Annual Meeting of Japan Society of Gene and Cell Therapy (2023/9/11-13 Osaka).
Dec. 2022
Our paper has been published in Scientific Reports.
Oct. 2022
Dr.Kasuya, and Mohamed gave a presentation at The 14th International Oncolytic Virotherapy Conference (IOVC)(2022/10/23-26 Karuizawa).
Sep. 2022
Dr.Naoe, Mohamed, and Mona gave a presentation at the 81th Annual Meeting of the Japanese Cancer-Association (2022/9/29-10/1 Yokohama).
July 2022
Dr.Naoe gave a presentation at the 26th Annual Meeting of the Japanese Association of Cancer Immunology (2022/7/22 Shimane).
July 2022
Dr.Naoe, Mohamed, Mona, and Patricia gave a presentation at the 28th Annual Meeting of Japan Society of Gene and Cell Therapy (2022/7/14―16 Hakata).
Nov. 2021
Our paper has been published in Nagoya Journal of Medical Science.
Oct. 2021
Dr.Kasuya gave a presentation at the 6th Annual Oncolytic Virotherapy Summit (2021/10/26〜28 Boston: online).
Sep. 2021
Mohamed gave poster presentation at the 80th Annual Meeting of the Japanese Cancer-Association (2021/9/30〜10/2 Yokohama)
Jul. 2021
Our paper has been published in International Journal of Cancer.
Jun. 2021
Our paper has been published in MDPI Cells.
Oct. 2019
Dr.Kasuya gave a presentation at the 12th International Oncolytic Virotherapy Conference.(Rochester,America)
Apr. 2019
Dr.Kasuya gave a presentation at the ANTI-CANCER DRUG DISCOVERY 2019.(Tanta,Egypt)
Apr. 1 2019
"Members" page was updated.
May. 28 2018
"Members" page was updated.
Apr. 2018 Dr.Kasuya gave a presentation at the International Oncolytic Virus Conference.(Oxford,England)
Jan. 4 2018
"Members" page was updated.
Jun. 1 2017
"Members" page was updated.
Mar.13 2017
Our paper was published in an online journal, Oncolytic Virotherapy (Volume 2017-6).
Title: Curative effect of HF10 on liver and peritoneal metastasis mediated by host antitumor immunity
Nov. 11 2016